CorMedix Reports Strong Q1 Revenue & Net Income; Material Weakness Persists, DefenCath Reimbursement to Decline

summarizeSummary

CorMedix posted strong Q1 2026 financial results, but faces ongoing internal control issues and an anticipated decline in DefenCath reimbursement later this year, while also executing a share repurchase.

check_boxKey Events · Earnings and Guidance · CRMD

• Strong Q1 Financial Performance

  CorMedix reported Q1 2026 total revenue of $127.4 million, a 226% increase year-over-year, and net income of $38.6 million, up 87%, largely due to the Melinta acquisition and DefenCath sales.

• DefenCath Reimbursement Headwind Expected

  The company anticipates a significant reduction in DefenCath net pricing in the second half of 2026 due to a transition in CMS reimbursement methodology, though 2027 payments could increase.

• Persistent Material Weakness in Internal Controls

  The material weakness in internal control over financial reporting, previously disclosed in the 2025 10-K, remains unremediated as of March 31, 2026.

• Share Repurchase Program Activity

  CorMedix repurchased 1.6 million shares for $11.1 million during the first quarter of 2026 under its $75 million authorization, with $63.9 million remaining.

auto_awesomeAnalysis · CRMD · Life Sciences

CorMedix Inc. reported robust first-quarter 2026 financial results, with significant increases in revenue and net income, primarily driven by the Melinta acquisition and strong DefenCath sales. However, the company continues to report a material weakness in its internal controls over financial reporting, which remains unremediated. A notable future headwind is the expected significant reduction in DefenCath net pricing in the second half of 2026 due to a transition in CMS reimbursement methodology. The company also actively repurchased shares under its authorized program.